Clinical Trials Logo

Hepatic Impairment clinical trials

View clinical trials related to Hepatic Impairment.

Filter by:

NCT ID: NCT05045482 Recruiting - Cirrhosis Clinical Trials

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

Start date: October 21, 2021
Phase: Phase 1
Study type: Interventional

A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease

NCT ID: NCT04950764 Recruiting - Hepatic Impairment Clinical Trials

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Start date: September 17, 2021
Phase: Phase 1
Study type: Interventional

The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

NCT ID: NCT04819464 Recruiting - Healthy Clinical Trials

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod

Start date: August 19, 2021
Phase: Phase 1
Study type: Interventional

This is a prospective, open-label, single-dose, phase 1 study, to assess the effect of mild and moderate hepatic impairment on the pharmacokinetics of cenerimod (ACT-334441).

NCT ID: NCT04694365 Recruiting - Healthy Subjects Clinical Trials

Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function

Start date: November 6, 2020
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the safety and pharmacokinetics of Fluzoparib in subjects with impaired liver function in comparison with healthy subjects ,to develop dose recommendations for patients with hepatic impairment.

NCT ID: NCT04631549 Recruiting - Clinical trials for Healthy Participants

An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

Start date: February 3, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate SHR3680 in participants with different levels of liver function

NCT ID: NCT04494269 Recruiting - Healthy Clinical Trials

A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls

Start date: September 8, 2020
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to compare the pharmacokinetic and safety of tegoprazan following single oral dose in subjects with hepatic impairment versus healthy control.

NCT ID: NCT04469920 Recruiting - Hepatic Impairment Clinical Trials

Hepatic Impairment, Cholestatic Liver Disease, & NASH With Advanced Fibrosis & Normal Hepatic Function

Start date: July 16, 2020
Phase: Phase 1
Study type: Interventional

This will be a Phase 1, Open-label Study of Participants with Hepatic Impairment, Cholestatic Liver Disease, and NASH with Advanced Fibrosis and Normal Hepatic Function

NCT ID: NCT04271488 Recruiting - Hepatic Impairment Clinical Trials

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

Start date: February 27, 2020
Phase: Phase 1
Study type: Interventional

The primary purpose of the study is to evaluate the effects of mild and moderate hepatic impairment on PK of tasurgratinib after a single dose administration.

NCT ID: NCT04241835 Recruiting - Hepatic Impairment Clinical Trials

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Start date: January 28, 2020
Phase: Phase 1
Study type: Interventional

This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat. The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe hepatic (liver) impairment will be compared with participants with advanced malignancies and normal hepatic function. An advanced malignancy is a cancer that has recurred (come back) after prior treatment or hasn't controlled with treatment. The trial will also study the safety of the study drug in participants (how well it is tolerated).

NCT ID: NCT04154774 Recruiting - Hepatic Impairment Clinical Trials

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

Start date: November 7, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the single-dose pharmacokinetic (PK) of apalutamide in participants with severe hepatic impairment relative to participants with normal hepatic function.